Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial

NCT07809724 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07809724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07809724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 30, 2026
Completion date
December 30, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorder (nmosd)